• LAST PRICE
    16.1300
  • TODAY'S CHANGE (%)
    Trending Down-1.1400 (-6.6010%)
  • Bid / Lots
    16.0900/ 6
  • Ask / Lots
    16.1400/ 2
  • Open / Previous Close
    17.2900 / 17.2700
  • Day Range
    Low 16.0800
    High 17.5034
  • 52 Week Range
    Low 7.6400
    High 30.1886
  • Volume
    256,110
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 17.27
TimeVolumeCGEM
09:32 ET860717.15
09:33 ET127317.01
09:35 ET10017.135
09:37 ET13017.3
09:39 ET10017.135
09:44 ET10017.21
09:46 ET100017.243649
09:48 ET491117.31
09:50 ET230017.24
09:51 ET151117.4586
09:57 ET117817.39
10:00 ET44517.32
10:02 ET48317.26
10:04 ET10017.26
10:06 ET790017.265
10:08 ET2285017.135
10:09 ET30017.135
10:11 ET71917.12
10:13 ET1220017.11
10:18 ET13517.0963
10:20 ET589816.82
10:22 ET20016.79
10:24 ET276616.75
10:26 ET557916.62
10:27 ET120516.7
10:29 ET1139516.69
10:31 ET290616.6
10:33 ET10016.54
10:36 ET10016.55
10:38 ET30016.52
10:40 ET200016.46
10:42 ET298616.39
10:44 ET350016.28
10:45 ET233516.34
10:47 ET100016.26
10:49 ET30016.24
10:51 ET20016.26
10:54 ET149316.25
10:56 ET50016.25
10:58 ET423416.32
11:00 ET10016.22
11:02 ET30016.3338
11:03 ET135316.3262
11:05 ET222916.23
11:07 ET82116.3388
11:09 ET40016.33
11:12 ET10016.29
11:16 ET55216.29
11:18 ET150016.25
11:20 ET97716.18
11:21 ET11916.175
11:25 ET10016.13
11:30 ET59916.17
11:32 ET20216.15
11:34 ET40016.14
11:36 ET179216.14
11:38 ET10016.16
11:41 ET178616.13
11:43 ET359016.305
11:50 ET294216.17
11:52 ET10016.13
11:54 ET10016.08
11:56 ET30016.14
11:57 ET40716.14
11:59 ET120016.19
12:01 ET20016.21
12:06 ET163316.3
12:08 ET10016.26
12:14 ET690816.27
12:17 ET10016.16
12:19 ET30016.135
12:21 ET23316.135
12:24 ET10016.08
12:26 ET883416.17
12:32 ET20016.165
12:33 ET314216.29
12:35 ET30016.34
12:37 ET20216.395
12:39 ET71416.395
12:42 ET61716.395
12:44 ET40016.39
12:48 ET21016.39
12:50 ET60016.3
12:51 ET100016.3201
12:53 ET10016.21
12:55 ET99516.32
12:57 ET160016.2393
01:00 ET50016.2
01:06 ET259716.28
01:09 ET60216.26
01:15 ET50016.2
01:22 ET210816.11
01:24 ET60716.14
01:26 ET50016.17
01:31 ET10016.16
01:33 ET35716.15
01:36 ET187016.155
01:38 ET277816.22
01:40 ET10016.1811
01:42 ET310016.24
01:45 ET10016.17
01:47 ET10016.195
01:49 ET40016.195
01:51 ET90016.155
01:54 ET107716.16
02:00 ET25916.13
02:02 ET160016.19
02:03 ET10016.19
02:12 ET130016.15
02:14 ET632016.13
02:16 ET83216.12
02:18 ET35716.12
02:20 ET210016.13
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCGEM
Cullinan Therapeutics Inc
1.0B
-5.6x
---
United StatesCRGX
CARGO Therapeutics Inc
1.0B
-6.1x
---
United StatesNUVB
Nuvation Bio Inc
1.0B
-1.3x
---
United StatesRAPP
Rapport Therapeutics Inc
983.9M
-14.4x
---
United StatesLENZ
LENZ Therapeutics Inc
983.2M
-3.9x
---
United StatesETNB
89Bio Inc
1.1B
-3.2x
---
As of 2024-11-12

Company Information

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Contact Information

Headquarters
One Main Street, Suite 1350CAMBRIDGE, MA, United States 02142
Phone
617-410-4650
Fax
302-655-5049

Executives

Independent Chairman of the Board
Anthony Rosenberg
President, Chief Executive Officer, Director
Nadim Ahmed
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Mary Fenton
Chief Scientific Officer
Jennifer Michaelson
Chief Legal and Compliance Officer, Company Secretary
Jacquelyn Sumer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.0B
Revenue (TTM)
$0.00
Shares Outstanding
58.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.07
EPS
$-2.88
Book Value
$10.58
P/E Ratio
-5.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.